3
Views
6
CrossRef citations to date
0
Altmetric
Research Article

Role of K+ Ion Channels in Lymphokine-Activated Killer (LAK) Cell Lytic Function

, &
Pages 571-582 | Published online: 28 Sep 2008
 

Abstract

Cells of the immune system possess K+ ion channels which have been implicated in various cellular functions including activation, differentiation and cytolytic function. To define the role of K+ ion channels in the lytic function of lymphokine-activated killer (LAK) cells, we investigated the effects of K+ channel blockers on their cytolytic activity. Results show that when LAK cell mediated cytolysis of AKIL-20 tumor cexis was carried out in the presence of: a) the K+ channel blocker, 4-aminopyridine (4-AP); b) the monoamine, serotonin (5-hydroxytryptamine; 5-HT); c) the serotonin agonist, quipazine; d) or the Ca++ dependent K+ Channel blocker, quinidine, the cytolytic activity of the LAK cells was inhibited in a dose-dependent manner. Preincubation of LAK effector cells also inhibited lysis in a dose-dependent manner, whereas preincubation of the AKIL-20 tumor target cells produced no inhibitory effects. This study demonstrates that K+ ion channels are involved in the LAK cell cytolytic process and that compounds, including neuroendocrine products, which modulate K+ ion channel function are capable of modulating the lytic activity of these effector cells.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.